1. Home
  2. CCS vs VRDN Comparison

CCS vs VRDN Comparison

Compare CCS & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCS
  • VRDN
  • Stock Information
  • Founded
  • CCS 2000
  • VRDN 2006
  • Country
  • CCS United States
  • VRDN United States
  • Employees
  • CCS N/A
  • VRDN N/A
  • Industry
  • CCS Homebuilding
  • VRDN Medical Specialities
  • Sector
  • CCS Consumer Discretionary
  • VRDN Health Care
  • Exchange
  • CCS Nasdaq
  • VRDN Nasdaq
  • Market Cap
  • CCS 1.7B
  • VRDN 1.5B
  • IPO Year
  • CCS 2014
  • VRDN N/A
  • Fundamental
  • Price
  • CCS $69.61
  • VRDN $18.72
  • Analyst Decision
  • CCS Buy
  • VRDN Strong Buy
  • Analyst Count
  • CCS 4
  • VRDN 11
  • Target Price
  • CCS $80.75
  • VRDN $38.80
  • AVG Volume (30 Days)
  • CCS 303.3K
  • VRDN 894.1K
  • Earning Date
  • CCS 10-22-2025
  • VRDN 08-06-2025
  • Dividend Yield
  • CCS 1.67%
  • VRDN N/A
  • EPS Growth
  • CCS N/A
  • VRDN N/A
  • EPS
  • CCS 8.26
  • VRDN N/A
  • Revenue
  • CCS $4,314,251,000.00
  • VRDN $305,000.00
  • Revenue This Year
  • CCS N/A
  • VRDN N/A
  • Revenue Next Year
  • CCS $10.62
  • VRDN $35,092.81
  • P/E Ratio
  • CCS $8.43
  • VRDN N/A
  • Revenue Growth
  • CCS 5.66
  • VRDN 5.90
  • 52 Week Low
  • CCS $50.42
  • VRDN $9.90
  • 52 Week High
  • CCS $108.42
  • VRDN $27.20
  • Technical
  • Relative Strength Index (RSI)
  • CCS 65.59
  • VRDN 55.80
  • Support Level
  • CCS $63.53
  • VRDN $18.12
  • Resistance Level
  • CCS $66.51
  • VRDN $20.05
  • Average True Range (ATR)
  • CCS 2.16
  • VRDN 1.02
  • MACD
  • CCS 0.17
  • VRDN -0.02
  • Stochastic Oscillator
  • CCS 84.94
  • VRDN 55.81

About CCS Century Communities Inc.

Century Communities Inc is engaged in the development, design, construction, marketing, and selling of single-family attached and detached homes. It has five homebuilding segments: West, Mountain, Texas, Southeast, and Century Complete. Its sixth reportable segment is financial services operations, which provides mortgage, title, and insurance services to homebuyers. It has acquired land for homebuilding operations with the primary intent to develop and construct single-family detached or attached homes for sale on the acquired land. The company sells homes through its sales representatives and independent real estate brokers. The company generates the majority of its revenue from the Mountain segment.

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Share on Social Networks: